This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Valtropin

LG Life Sciences Ltd.

Drug Names(s): somatropin [rDNA origin] for injection, Biosimilar Somatropin

Description: Valtropin is a recombinant human GH (rhGH). Valtropin is a biosimilar to Humatrope.

Deal Structure: In April 2000, BioPartners and LG Life Sciences entered into collaborative agreements to jointly develop, manufacture and commercialize a number of biopharmaceutical products, including interferon alpha, human growth hormone (daily and sustained-release formulations) and erythropoietin. The companies have co-developed Valtropin and a sustained release formulation of Valtropin.

Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for Valtropin in Europe, Japan and other parts of Asia.

In March 2007, Biopartners announced that it has been purchased in a deal worth $78M by Bioton S.A.

Partners: Bioton S.A.


Valtropin News

Pink Sheet Biosimilars


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug